Nexien BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nexien BioPharma generated cash of -$64,364, which is more than the previous year. Cash used in financing activities reached the amount of $33,400 last year. Net change in cash is therefore -$30,964.
Cash Flow
| 2015 | -46.73K | 0 | 46.73K |
|---|---|---|---|
| 2016 | -16.35K | 0 | 16.35K |
| 2017 | -129.53K | -201.67K | 575.95K |
| 2018 | -875.34K | -47.9K | 1.50M |
| 2019 | -643.38K | -30K | 0 |
| 2020 | -147.57K | 0 | 12K |
| 2021 | -90.74K | 0 | 98K |
| 2022 | -75.14K | 0 | 174K |
| 2023 | -81.75K | 0 | 0 |
| 2024 | -64.36K | 0 | 33.4K |
NXEN Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 35.14K | 116.89K | 18.04K | 10.78K | 146.35K | 819.73K | 242.77K | -1.97K | 0 | 0 |
Operating activities | ||||||||||
Net income | -239.11K | -361.90K | -626.35K | -1.85M | -2.67M | -4.30M | -1.28M | -258.65K | -20.98K | -48.44K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 49.76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 0 | 203K | 379.00K | 348.95K | 52.13K | 1.89M | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 203K | 379.00K | 348.95K | 52.13K | 1.89M | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 15K | 0 | -138.33K | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
Accounts payable | 29.53K | 3.24K | 14.02K | 2.88K | -26.09K | -42.53K | 0 | 0 | 0 | -55 |
Cash generated by operating activities | -64.36K | -81.75K | -75.14K | -90.74K | -147.57K | -643.38K | -875.34K | -129.53K | -16.35K | -46.73K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -86.67K | 0 | 0 |
Investments In Property Plant And Equipment | 4 | 0 | 0 | 0 | 0 | -30K | -35K | -65K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | -12.9K | -136.67K | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | -30K | -47.9K | -201.67K | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 2.25K | 0 | 0 | 0 | 1.52M | 575.95K | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 20K | 0 | 146.75K | -78K | -12K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 33.4K | 0 | 174K | 98K | 12K | 0 | 1.50M | 575.95K | 16.35K | 46.73K |
Net Change In Cash | -30.96K | -81.75K | 98.85K | 7.25K | -135.57K | -673.38K | 576.96K | 244.75K | 0 | 0 |
Cash at end of period | 4.18K | 35.14K | 116.89K | 18.04K | 10.78K | 146.35K | 819.73K | 242.77K | 0 | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |